News
From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction. Join Drs Feldman and Armstrong as they discuss.
Johnson & Johnson boosted its full-year outlook as it posted better-than-expected profit and sales in the second quarter. The healthcare-products company said Tuesday it now expects adjusted per-share ...
One of the more serious side effects from immune checkpoint inhibitor (ICI) therapies for cancer is new-onset or worsened ...
A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...
1d
Everyday Health on MSNHow to Spot and Treat Inverse PsoriasisInverse psoriasis, which causes painful lesions on sensitive skin folds, can be hard to treat. Find out more about this type of psoriasis.
Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.
John McEnroe is on the call of the men's championship match at Wimbledon on Sunday. The iconic American tennis player, who ...
Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...
2d
Health on MSNWhat To Know About Guttate Psoriasis in Adults and ChildrenMedically reviewed by Katlein Franca, MD Guttate psoriasis causes small, round bumps. It's typically triggered by a Streptococcus (strep) bacteria infection. Guttate psoriasis most commonly affects ...
Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease ...
A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results